Stryker (SYK) Tests Its Valuation After Sonopet 3 Clearance

Stryker (SYK) just received 510(k) clearance from the U.S. Food and Drug Administration for Sonopet 3, a new ultrasonic bone and soft tissue removal platform shaped by extensive surgeon feedback. For context, Stryker’s recent 1 month share price return of 11.63% and 7 day move of 4.72% have come after a tougher patch, with the stock down 7.02% over 3 months and its 1 year total shareholder return declining 18.95%. Meanwhile, the 3 year and 5 year total shareholder returns of 22.32% and 20.59%...